Edition:
India

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

2.80USD
18 Sep 2020
Change (% chg)

$-0.15 (-5.08%)
Prev Close
$2.95
Open
$2.95
Day's High
$2.96
Day's Low
$2.75
Volume
13,107,457
Avg. Vol
849,455
52-wk High
$13.71
52-wk Low
$2.46

Latest Key Developments (Source: Significant Developments)

Akebia Therapeutics Announces Top-Line Results From Its Pro2tect Global Phase 3 Program Of Vadadustat
Thursday, 3 Sep 2020 

Sept 3 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM ITS PRO2TECT GLOBAL PHASE 3 PROGRAM OF VADADUSTAT FOR TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULT PATIENTS NOT ON DIALYSIS.AKEBIA THERAPEUTICS INC - PRO2TECT ACHIEVES PRIMARY AND KEY SECONDARY EFFICACY ENDPOINTS.AKEBIA THERAPEUTICS INC - PRO2TECT DOES NOT MEET PRIMARY SAFETY MACE ENDPOINT.AKEBIA THERAPEUTICS - BELIEVES TOTALITY OF DATA FROM GLOBAL PHASE 3 PROGRAM SUPPORTS NDA SUBMISSION FOR NON-DIALYSIS, DIALYSIS INDICATIONS.AKEBIA THERAPEUTICS INC - COMPANY REMAINS ON TRACK TO SUBMIT NDA.AKEBIA THERAPEUTICS - CO, OTSUKA PHARMACEUTICAL CO. LTD., WORKING TO PREPARE A MARKETING AUTHORIZATION APPLICATION FOR SUBMISSION TO EMA.  Full Article

Akebia Therapeutics Announces Settlement Of Auryxia Patent Litigation With Par Pharmaceutical
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS® ANNOUNCES SETTLEMENT OF AURYXIA® PATENT LITIGATION WITH PAR PHARMACEUTICAL.AKEBIA THERAPEUTICS INC - KERYX BIOPHARMACEUTICALS AND ITS LICENSOR PANION & BF BIOTECH ENTERED INTO A SETTLEMENT AND LICENSE AGREEMENT.AKEBIA THERAPEUTICS INC - RESOLVES PATENT LITIGATION IN RESPONSE TO PAR'S ANDA SEEKING APPROVAL TO MARKET A GENERIC VERSION OF AURYXIA TABLETS.AKEBIA THERAPEUTICS - COS WILL GRANT PAR A LICENSE TO MARKET ITS GENERIC VERSION OF AURYXIA IN UNITED STATES BEGINNING ON MARCH 20, 2025 OR EARLIER.AKEBIA THERAPEUTICS INC - PARTIES WILL TERMINATE ALL ONGOING HATCH-WAXMAN LITIGATION BETWEEN KERYX AND PANION AND PAR.AKEBIA THERAPEUTICS INC - AGREEMENT IS CONFIDENTIAL AND SUBJECT TO REVIEW BY U.S. FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE.  Full Article

Akebia Therapeutics Says Anticipates Delayed Filing Of Annual Report On Form 10-K
Tuesday, 19 Mar 2019 

March 18 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES PRELIMINARY FULL-YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKEBIA THERAPEUTICS INC - ENDED 2018 WITH CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES OF $321.6 MILLION.AKEBIA - SEES CASH RESOURCES, INCLUDING PREPAID QTRLY COMMITTED COST-SHARE COLLABORATION PARTNER FUNDING, TO FUND CURRENT OPERATING PLAN INTO Q3 2020.AKEBIA THERAPEUTICS - ANTICIPATES DELAYED FILING OF ANNUAL REPORT ON FORM 10-K FOR FISCAL YEAR ENDED DEC 31, 2018.AKEBIA THERAPEUTICS INC QTRLY PRELIMINARY COLLABORATION REVENUES $53.0 MILLION VERSUS $90.6 MILLION.AKEBIA THERAPEUTICS INC - NO REVENUE WAS RECOGNIZED UNDER MTPC COLLABORATION AGREEMENT IN Q4 OF 2018.AKEBIA THERAPEUTICS INC QTRLY PRELIMINARY PRE-TAX NET LOSS OF $88.4 MILLION VERSUS PRE-TAX NET INCOME OF $15.5 MILLION.  Full Article

Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA DUE TO CHRONIC KIDNEY DISEASE.EACH STUDY, ONE IN NON-DIALYSIS DEPENDENT SUBJECTS AND ONE IN HEMODIALYSIS-DEPENDENT SUBJECTS, MET ITS PRIMARY ENDPOINT.MITSUBISHI TANABE PHARMA CORPORATION EXPECTS TO SUBMIT A JAPANESE NEW DRUG APPLICATION IN 2019.  Full Article

Nantahala Capital Management, Llc Reports 4.7 pct Stake In Akebia Therapeutics As Of Dec 12
Saturday, 22 Dec 2018 

Dec 21 (Reuters) - :NANTAHALA CAPITAL MANAGEMENT, LLC REPORTS 4.7 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF DEC 12, 2018 - SEC FILING.NANTAHALA CAPITAL MANAGEMENT, LLC - HAD PREVIOSULY REPORTED 9.8 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF SEPT 25, 2018.  Full Article

Keryx Signs Letter Of Intent with Akebia Therapeutics Related To Auryxia
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Keryx Biopharmaceuticals ::ON OCT 24, ENTERED LETTER AGREEMENT WITH PANION & BF BIOTECH, AND AKEBIA THERAPEUTICS RELATED TO AURYXIA - SEC FILING.PANION AGREED TO RESCIND ANY AND ALL PRIOR TERMINATION THREATS OR NOTICES RELATING TO LICENSE AGREEMENT.PANION WAIVED ITS RIGHTS TO TERMINATE LICENSE AGREEMENT BASED ON ANY BREACH BY KERYX OF CERTAIN OBLIGATION.TERMS INCLUDE ESTABLISHING A JOINT STEERING COMMITTEE WITH PANION, AKEBIA REPRESENTATIVES RELATED TO FEXERIC IN EUROPE.  Full Article

Akebia Therapeutics Says Co Entered First Amendment To Agreement & Plan Of Merger With Alpha Therapeutics, Co's Unit And Keryx
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS SAYS CO ENTERED FIRST AMENDMENT TO AGREEMENT & PLAN OF MERGER WITH ALPHA THERAPEUTICS, CO'S UNIT AND KERYX - SEC FILING.AKEBIA THERAPEUTICS - FIRST AMENDMENT PROVIDES AT MERGER CO MUST CAUSE INCREASE IN SIZE OF THE AKEBIA BOARD TO 10 DIRECTORS.AKEBIA THERAPEUTICS - FIRST AMENDMENT PROVIDES AT MERGER ADDITIONAL DIRECTOR SHALL SERVE AS CHAIRPERSON OF AKEBIA BOARD.  Full Article

Akebia plunges 73% after anemia treatment fails to meet safety goal

Akebia Therapeutics Inc said on Thursday its experimental drug failed to meet the main safety goal in a late-stage trial testing the treatment in patients with anemia due to chronic kidney disease and not undergoing dialysis.